Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2017

Planlagt Fastgjort Låst Flyttet Genmab
4.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Legolas23L Offline
    Legolas23L Offline
    Legolas23
    wrote on sidst redigeret af
    #115

    Mon ikke der kigges langt efter Alcyone data

    1 Reply Last reply
    0
    • V Offline
      V Offline
      Vitus
      wrote on sidst redigeret af
      #116

      Gdn55: Hvad generer dig ?

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #117

        Alcyone kommer som late breaker hvis den kommer, men Genmab må have stor tiltro til dette siden de specifikt nævner i dagens ASH meddelelse, at nævnte abstracts ikke inkluderer late breaker abstracts

        1 Reply Last reply
        0
        • J Offline
          J Offline
          jkj
          wrote on sidst redigeret af
          #118

          ja sådan tolker jeg det også

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #119

            ADCT 301. Nu = Camidanlumab Tesirine !!! pts with HL have been treated with doses ≥30 µg/kg, with an ORR of 63.6% (14/22) and a complete response rate of 27.3% (6/22); ORRs by prior treatment were: 13/21 (61.9%) pts who previously received brentuximab vedotin (BV), 10/16 (62.5%) pts who previously received a checkpoint inhibitor and BV

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #120

              Link Preview Image
              Webprogram Unavailable

              favicon

              (ash.confex.com)

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #121

                Det ser nu ret godt ud gentogen med ADCT-301

                1 Reply Last reply
                0
                • V Offline
                  V Offline
                  Vitus
                  wrote on sidst redigeret af
                  #122

                  Vores sprogbrug er forskellig......heldigvis for det !

                  1 Reply Last reply
                  0
                  • A Offline
                    A Offline
                    AaBforever
                    wrote on sidst redigeret af
                    #123

                    Spændende når vi når 21. nov...

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #124

                      Vil skal vel nok til at kalde det Cami-t - ikke at forveksle med camille-te 😉

                      1 Reply Last reply
                      0
                      • A Offline
                        A Offline
                        AaBforever
                        wrote on sidst redigeret af
                        #125

                        Accepteret late breaking med outstanding data på Alcyone er efter min mening den eneste kortsigtede kurstrigger.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #126

                          Tja, med mindre recepttallene pludselig begynder at sparke røv

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #127

                            Hvis bare safety profilen for Cami-t er som camille te, så kald du det hvad du vil !!

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #128

                              .. eller med mindre Winkel synger en sang fra de varme lande på næste onsdag.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #129

                                ligeledes spændende fra Karyopharm (selinexor):

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #130

                                  The four STOMP presentations will include updated data from the arms evaluating selinexor in combination with Velcade® (bortezomib) and low-dose dexamethasone (SVd), selinexor in combination with Pomalyst® (pomalidomide) and low-dose dexamethasone (SPd), and selinexor in combination with Revlimid® (lenalidomide) and low-dose dexamethasone (SRd), and preliminary data from the arm evaluating selinexor in combination with Darzalex® (daratumumab) and low-dose dexamethasone (SDd).

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #131

                                    Link Preview Image
                                    Webprogram Unavailable

                                    favicon

                                    (ash.confex.com)

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #132

                                      Conclusions – Selinexor 100 mg QW, can be combined safely with daratumumab and dex. The activity observed in the first 3 pts is promising with all 3 pts responding to therapy. Enrollment is ongoing and updated data from 100 mg QW cohort, 100 mg QW expansion, and full phase 1 will be updated and presented.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #133

                                        Poseida Therapuetics paper on CAR-T; apparantly they are collaborating with J&J’s Janss
                                        en to develop this... didn't know that... https://ash.confex.com/ash/2017/webprogram/Paper108439.html

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #134

                                          After 3 years of median follow-up, single-agent DARA continues to demonstrate a favorable safety profile with no new safety signals. Deep and durable responses continue to be maintained in a subset of these heavily pretreated patients. With over one-third of patients remaining alive after 3 years of study entry, these findings highlight the activity of single-agent DARA

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger